Genmab

Genmab A/S
Company type	Publicly traded
Traded as	OMX: GEN
Industry	Biotechnology
Founded	February 1999
Headquarters	Copenhagen, Denmark
Key people	Jan van de Winkel (CEO)
Products	Daratumumab (DARZALEX), Ofatumumab (Arzerra)
Total equity	19,121 million DKK (2020)
Website	www.genmab.com

Genmab A/S is a Danish-American biotechnology company. It was started in February 1999 by Florian Schönharting.

The company's main office is in Copenhagen. It also has offices in Utrecht, Netherlands, and Princeton, USA. Genmab is listed on the Nasdaq Copenhagen stock exchange.^[2]^[3]

Products

Ofatumumab (Arzerra): A medicine for certain types of leukemia.
Daratumumab (DARZALEX): A human CD38 antibody. The FDA gave this medicine "Breakthrough Therapy" status because it showed great promise in treating cancer patients who had no other options.^[4]

History

Genmab started as a spinoff of an American company called Medarex. BankInvest provided the early money to start the business.^[5]

In 2008, the CEO Lisa Natale Drakeman was the highest-paid director in Denmark, earning 28.6 million DKK.^[6] However, the company faced hard times in 2009. They lost 965 million DKK^[7] and had to lay off more than half of their workers (about 300 people).^[8]

In 2010, Jan van de Winkel became the new CEO. Under his leadership, the company recovered its value. He has over 20 years of experience and has written over 300 scientific papers.^[9]

References

↑ Annual Report 2021
↑ GEN, Genmab, (DK0010272202) - Nasdaq
↑ "About us". Archived from the original on 10. september 2013. Retrieved 16. september 2013. {{cite web}}: Check date values in: |access-date= and |archive-date= (help)
↑ "FDA grants Breakthrough Therapy status to daratumumab". Euroinvestor. 1. maj 2013. {{cite news}}: Check date values in: |date= (help)^{[permanent dead link]}
↑ "FDA Grants GSK and Genmab's Arzerra Breakthrough Therapy Designation". GlobeNewswire. 13. september 2013. {{cite news}}: Check date values in: |date= (help)
↑ Kåre Pedersen (5. juni 2008). "EU countries want laws against high bonuses". Information. {{cite news}}: Check date values in: |date= (help)
↑ Ritzau (24. februar 2009). "Genmab hopes to cut losses in half". Information. {{cite news}}: Check date values in: |date= (help)
↑ "Genmab fires half of its employees". TV2. 5. november 2009. Archived from the original on 2009-11-15. Retrieved 2026-01-14. {{cite news}}: Check date values in: |date= (help)
↑ "Genmab - Jan van de Winkel". Archived from the original on 2016-08-15. Retrieved 14. juli 2016. {{cite web}}: Check date values in: |access-date= (help)

Other websites

Genmab official website

This short article can be made longer. You can help Wikipedia by adding to it.

[aarsrap-1] Annual Report 2021

[2] GEN, Genmab, (DK0010272202) - Nasdaq

[3] "About us". Archived from the original on 10. september 2013. Retrieved 16. september 2013. {{cite web}}: Check date values in: |access-date= and |archive-date= (help)

[4] "FDA grants Breakthrough Therapy status to daratumumab". Euroinvestor. 1. maj 2013. {{cite news}}: Check date values in: |date= (help)^{[permanent dead link]}

[5] "FDA Grants GSK and Genmab's Arzerra Breakthrough Therapy Designation". GlobeNewswire. 13. september 2013. {{cite news}}: Check date values in: |date= (help)

[6] Kåre Pedersen (5. juni 2008). "EU countries want laws against high bonuses". Information. {{cite news}}: Check date values in: |date= (help)

[7] Ritzau (24. februar 2009). "Genmab hopes to cut losses in half". Information. {{cite news}}: Check date values in: |date= (help)

[8] "Genmab fires half of its employees". TV2. 5. november 2009. Archived from the original on 2009-11-15. Retrieved 2026-01-14. {{cite news}}: Check date values in: |date= (help)

[9] "Genmab - Jan van de Winkel". Archived from the original on 2016-08-15. Retrieved 14. juli 2016. {{cite web}}: Check date values in: |access-date= (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]